Stay informed Sign up for our newsletter and be the first to know.
Stay informed Sign up for our newsletter and be the first to know.
Brilliant Investment Thinking by Advisers for Advisers.
ASX
-0.70%
S&P
-2.64%
AUD
$0.70

The alternative asset class that can change people’s lives

Healthcare and life sciences is emerging as an economically resilient alternative asset class, given that the industry has huge tailwinds in the form of the demographic force of an ageing population around the world. Plus, there is the growing demand from lifestyle diseases – illnesses that arise from day-to-day life habits of an individual – and the expansion on the back of digital health and AI.

Read More

ASX edges ahead after mid-week nosedive

Another weekly gain, inflation headwinds, Kogan canned, IPOs pulled The ASX200 (ASX:XJO) finished Friday on a positive note, up 0.2%, delivering a weekly gain of the same amount. For the day, only...
Read More

ASX lifts a touch to overcome tech losses

ASX delivers small gain, Future Fund leads renewables deal  The ASX200 (ASX:XJO) finished slightly higher, adding 0.1% to commence the week.  The IT sector continues to feel a great deal of selling...
Read More

ASX to open higher, strong US lead

ASX to open higher, strong US lead, Commonwealth Bank (ASXLCBA) hit with ASIC investigation The ASX200 (ASX:XJO) finished 1.7% higher to start the week, rebounding quickly from Friday's so-called 'bloodbath'. Once again,...
Read More

Cheaper, more diversified and delivering

With attention focused on the record-breaking run of the Dow Jones Industrial Average (DJIA), which now sits above 30,000 points for the first time, smaller companies continue to be neglected....
Read More

The power of long-short in a pandemic market

Long-short strategies, which involve giving a fund manager the flexibility to profit when share prices rise or fall, were gaining traction before the pandemic. The trend has continued to accelerate...
Read More

Thinking forward: Three ASX biotech stars

And still they keep coming - here's the fourth instalment of our series on the fascinating ASX cohort of medical device developers. As always, don't let the impressive sexiness of...
Read More

Growth managers continue to shine

It's been a while since "value investing" made sense: the style has suffered a dreadful stretch of performance since the 2008 financial crisis. The 'Warren Buffett' mantra of buying low...
Read More

Governments hurt pensions adequacy

Australia has slipped from third place in the world rankings for adequacy, sustainability and integrity of our super system to fourth place, being leap-frogged by new entrant Israel. The impact...
Read More